Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials
Lancet Psychiatry. 2025 Dec;12(12):906-920. doi: 10.1016/S2215-0366(25)00296-2. ABSTRACT BACKGROUND: There are no pharmacotherapies available for cognitive impairment associated with schizophrenia (CIAS). The CONNEX programme investigated the …